The case for & against
Bull & Bear analysis
Bullish
Apyx Medical, trading under the ticker APYX, is an emerging innovator within the surgical aesthetics sector, specializing in advanced energy devices aimed at body contouring and skin rejuvenation. The company is strategically positioned to leverage the growing demand for aesthetic treatments, especially as more patients utilize GLP-1 medications, leading to significant interest in body contouring procedures due to associated weight loss. Apyx Medical focuses on integrating multiple modalities into their flagship Aon Body Contouring System, allowing for a comprehensive approach in the market.
Bull says
- ↑Surgical aesthetics sales rose 36% YoY to $10.7M on Aon traction.
- ↑Q1 2026 revenue grew 32% YoY to $12.5M; gross margin 63.5%.
- ↑2026 revenue guidance raised to $59–60M; cash position $31.1M.
- ↑FDA cleared Aon for power liposuction, expanding multi-modality offering.
- ↑Cash burn reduced to $0.6M in Q1; net loss narrowed to $2.1M.
- ↑Strong momentum and positive revision sentiment support near-term price upside.
Bear says
- ↓Aon adoption remains in early stages, risking slower revenue ramp-up.
- ↓Growth hinge on FDA approvals; delays could stall new features.
- ↓OEM segment revenue expected to decline, pressuring overall profitability.
- ↓Cash flow could tighten if growth misses projections in downturns.
- ↓Customer uptake may fluctuate with GLP-1 trends, boosting volatility.
- ↓Negative earnings yield and weak profitability metrics raise financial concerns.
Earnings Call · Q1 2026 · Mgmt. Guidance
Updated 05-10-2026bullish
Transcript signals
Bull points
- we reported total quarterly revenue of $12.5 million compared to $9.4 million in the same period last year.
- Notably, while demand from our existing generator and Renuvion customer base continues to be strong, we are also generating a steady increase in engagement from new accounts, reflecting growing market awareness of Aon and increasing confidence in the breadth of its capabilities.
- As a result, we are seeing strong market receptivity, reinforcing our view that Aon is addressing a meaningful unmet need and adoption remains in the early stages.
Bear points
- While OEM segment sales increased for the three-month period with an increased focus on surgical aesthetics, we expect the OEM segment revenue will decrease for the year and that this trend will continue over time.
Read full transcript analysis ›